Embecta Q4 revenue $281.9M (+2.7%); guides FY2024 revenue down 1-3%

Embecta Corp.

2023-FY EPS reported $1.22 revenue$1,120,800,000

Q4 GAAP EPS $0.10, adjusted EPS $0.59; full-year adjusted EPS $2.99.
FY2024 revenue guidance $1,085-1,105M (reported -3% to -1%); adj. EPS $1.90-$2.10.
Dividend declared $0.15/share, payable Dec 15, 2023, record Dec 4.
Added as exclusive/dual-preferred brand with three top Medicare Part D payers starting Jan 2024.
Type 2 closed loop insulin pump development on track with FDA Breakthrough Device Designation.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Embecta Corp. updated its the quarter and fiscal year ended September 30, 2023 guidance (initiated).

Period: the quarter and fiscal year ended September 30, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

Embecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance

View on SEC.gov

Browse all earnings releases →

Embecta Corp. filing history →

Source: SEC EDGAR

accession 0001872789-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.